Top

Published in:

01-12-2021 | Nausea | Special Article

Medical management of malignant bowel obstruction in patients with advanced cancer: 2021 MASCC guideline update

Authors: Mellar Davis, David Hui, Andrew Davies, Carla Ripamonti, Andreia Capela, Giulia DeFeo, Egidio Del Fabbro, Eduardo Bruera

Published in: Supportive Care in Cancer | Issue 12/2021

Abstract

Background

Malignant bowel obstruction (MBO) is a frequent complication in patients with advanced cancer, particularly colon or gynecological malignancies. MASCC previously published a guideline for symptom management of MBO in 2017. This is a 5-year update.

Method

A systematic search and review of relevant literature includes a review published in 2010 and 2017. The guideline update used the same literature search process as followed in 2015. The dates of the new search included 2015 up to February 2, 2021. The guidelines involved the pharmacologic management of nausea and vomiting in malignant bowel obstruction (MBO) only. Only randomized trials were included in the updated guideline as evidence. The evidence was reviewed by the panel and the MASCC criteria for establishing a guideline were followed using MASCC level of grading and category of evidence.

Results

There was one systematic review and 3 randomized trials accepted as evidence from 257 abstracts. Octreotide is effective in reducing gastrointestinal secretions and colic and thereby reduces nausea and vomiting caused by MBO. Scopolamine butylbromide is inferior to octreotide in the doses used in the comparison study. Olanzapine or metoclopramide may be effective in reducing nausea and vomiting secondary to partial bowel obstructions. The panel suggests using either drug. Additional studies are needed to clarify benefits. Haloperidol has been used by convention as an antiemetic but has not been subjected to a randomized comparison. Ranitidine plus dexamethasone may be effective in reducing nausea and vomiting from MBO but cannot be recommended until there is a comparison with octreotide.

Discussion

Octreotide remains the drug of choice in managing MBO. Ranitidine was used in one randomized trial in all participants and so its effectiveness as a single drug is not known until there is a randomized comparison with octreotide. Antiemetics such as metoclopramide and olanzapine may be effective, but we have very few randomized trials of antiemetics in MBO.

Conclusion

The panel recommends octreotide in non-operable MBO. Randomized trials are needed to clarify ranitidine and antiemetic choices.

Available only for authorised users

Huang X, Xue J, Gao M et al (2020) Medical management of inoperable malignant bowel obstruction. Ann Pharmacother. 55(9):1134–1145. https://doi.org/10.1177/1060028020979773

Ripamonti CI, Easson AM, Gerdes H (2008) Management of malignant bowel obstruction. Eur J Cancer. 44(8):1105–1115PubMedCrossRef

Ripamonti C, Bruera E (2002) Palliative management of malignant bowel obstruction. Int J Gynecol Cancer. 12(2):135–143PubMedCrossRef

Soriano A, Davis MP (2011) Malignant bowel obstruction: individualized treatment near the end of life. Cleve Clin J Med. 78(3):197–206PubMedCrossRef

Ang SK, Shoemaker LK, Davis MP (2010) Nausea and vomiting in advanced cancer. Am J Hosp Palliat Care. 27(3):219–225PubMedCrossRef

Fainsinger RL, Spachynski K, Hanson J, Bruera E (1994) Symptom control in terminally ill patients with malignant bowel obstruction (MBO). J Pain Symptom Manage. 9(1):12–18PubMedCrossRef

Bleicher J, Lambert LA (2021) A palliative approach to management of peritoneal carcinomatosis and malignant ascites. Surg Oncol Clin N Am. 30(3):475–490PubMedCrossRef

Davis MP, Hallerberg G (2010) Palliative Medicine Study Group of the Multinational Association of Supportive Care in C. A systematic review of the treatment of nausea and/or vomiting in cancer unrelated to chemotherapy or radiation. J Pain Symptom Manage. 39(4):756–767PubMedCrossRef

Walsh D, Davis M, Ripamonti C, Bruera E, Davies A, Molassiotis A (2017) 2016 Updated MASCC/ESMO consensus recommendations: management of nausea and vomiting in advanced cancer. Support Care Cancer. 25(1):333–340PubMedCrossRef

10.

Ripamonti C, De Conno F, Ventafridda V, Rossi B, Baines MJ (1993) Management of bowel obstruction in advanced and terminal cancer patients. Ann Oncol. 4(1):15–21PubMedCrossRef

11.

Ripamonti C, Panzeri C, Groff L, Galeazzi G, Boffi R (2001) The role of somatostatin and octreotide in bowel obstruction: pre-clinical and clinical results. Tumori. 87(1):1–9PubMedCrossRef

12.

Mercadante S, Ripamonti C, Casuccio A, Zecca E, Groff L (2000) Comparison of octreotide and hyoscine butylbromide in controlling gastrointestinal symptoms due to malignant inoperable bowel obstruction. Support Care Cancer. 8(3):188–191PubMedCrossRef

13.

Ripamonti C, Mercadante S, Groff L, Zecca E, De Conno F, Casuccio A (2000) Role of octreotide, scopolamine butylbromide, and hydration in symptom control of patients with inoperable bowel obstruction and nasogastric tubes: a prospective randomized trial. J Pain Symptom Manage. 19(1):23–34PubMedCrossRef

14.

Mercadante S, Casuccio A, Mangione S (2007) Medical treatment for inoperable malignant bowel obstruction: a qualitative systematic review. J Pain Symptom Manage. 33(2):217–223PubMedCrossRef

15.

Mercadante S (1998) Scopolamine butylbromide plus octreotide in unresponsive bowel obstruction. J Pain Symptom Manage. 16(5):278–280PubMed

16.

Mercadante S (1995) Bowel obstruction in home-care cancer patients: 4 years experience. Support Care Cancer. 3(3):190–193PubMedCrossRef

17.

Mercadante S, Spoldi E, Caraceni A, Maddaloni S, Simonetti MT (1993) Octreotide in relieving gastrointestinal symptoms due to bowel obstruction. Palliat Med. 7(4):295–299PubMedCrossRef

18.

Shima Y, Ohtsu A, Shirao K, Sasaki Y (2008) Clinical efficacy and safety of octreotide (SMS201-995) in terminally ill Japanese cancer patients with malignant bowel obstruction. Jpn J Clin Oncol. 38(5):354–359PubMedCrossRef

19.

Shima Y, Yamaguchi K, Miyata Y, Hyodo I, Yagi Y, Honke Y (2004) A clinical study using octreotide in relieving gastrointestinal symptoms due to bowel obstruction in a terminally ill cancer patient. Gan To Kagaku Ryoho. 31(9):1377–1382PubMed

20.

Khoo D, Riley J, Waxman J (1992) Control of emesis in bowel obstruction in terminally ill patients. Lancet. 339(8789):375–376PubMedCrossRef

21.

Philip J, Lickiss N, Grant PT, Hacker NF (1999) Corticosteroids in the management of bowel obstruction on a gynecological oncology unit. Gynecol Oncol. 74(1):68–73PubMedCrossRef

22.

Mangili G, Franchi M, Mariani A, Zanaboni F, Rabaiotti E, Frigerio L, Bolis PF, Ferrari A (1996) Octreotide in the management of bowel obstruction in terminal ovarian cancer. Gynecol Oncol. 61(3):345–348PubMedCrossRef

23.

Ripamonti C, Twycross R, Baines M, Bozzetti F, Capri S, de Conno F, Gemlo B, Hunt TM, Krebs HB, Mercadante S, Schaerer R, Wilkinson P, Working Group of the European Association for Palliative Care (2001) Clinical-practice recommendations for the management of bowel obstruction in patients with end-stage cancer. Support Care Cancer. 9(4):223–233PubMedCrossRef

24.

De Conno F, Caraceni A, Zecca E, Spoldi E, Ventafridda V (1991) Continuous subcutaneous infusion of hyoscine butylbromide reduces secretions in patients with gastrointestinal obstruction. J Pain Symptom Manage. 6(8):484–486PubMedCrossRef

25.

Obita GP, Boland EG, Currow DC, Johnson MJ, Boland JW (2016) Somatostatin analogues compared with placebo and other pharmacologic agents in the management of symptoms of inoperable malignant bowel obstruction: a systematic review. J Pain Symptom Manage. 52(6):901–919 e901PubMedCrossRef

26.

Currow DC, Quinn S, Agar M, Fazekas B, Hardy J, McCaffrey N, Eckermann S, Abernethy AP, Clark K (2015) Double-blind, placebo-controlled, randomized trial of octreotide in malignant bowel obstruction. J Pain Symptom Manage. 49(5):814–821PubMedCrossRef

27.

Mariani P, Blumberg J, Landau A, Lebrun-Jezekova D, Botton E, Beatrix O, Mayeur D, Herve R, Maisonobe P, Chauvenet L (2012) Symptomatic treatment with lanreotide microparticles in inoperable bowel obstruction resulting from peritoneal carcinomatosis: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol. 30(35):4337–4343PubMedCrossRef

28.

McCaffrey N, Asser T, Fazekas B, Muircroft W, Agar M, Clark K, Eckermann S, Lee J, Joshi R, Allcroft P, Sheehan C, Currow DC (2020) Health-related quality of life in patients with inoperable malignant bowel obstruction: secondary outcome from a double-blind, parallel, placebo-controlled randomised trial of octreotide. BMC Cancer. 20(1):1050PubMedPubMedCentralCrossRef

29.

Clark K, Lam L, Currow D (2009) Reducing gastric secretions--a role for histamine 2 antagonists or proton pump inhibitors in malignant bowel obstruction? Support Care Cancer. 17(12):1463–1468PubMedCrossRef

30.

Itoh H (2006) Clinicopharmacological study of gastrointestinal drugs from the viewpoint of postmarketing development. Yakugaku Zasshi. 126(9):767–778PubMedCrossRef

31.

Peng X, Wang P, Li S, Zhang G, Hu S (2015) Randomized clinical trial comparing octreotide and scopolamine butylbromide in symptom control of patients with inoperable bowel obstruction due to advanced ovarian cancer. World J Surg Oncol. 13:50PubMedPubMedCentralCrossRef

32.

Kaneishi K, Imai K, Nishimura K, Sakurai N, Kohara H, Ishiki H, Kanai Y, Oyamada S, Yamaguchi T, Morita T, Iwase S (2020) Olanzapine versus metoclopramide for treatment of nausea and vomiting in advanced cancer patients with incomplete malignant bowel obstruction. J Palliat Med. 23(7):880–881PubMedCrossRef

33.

Owyang C (1994) Octreotide in gastrointestinal motility disorders. Gut. 35(3 Suppl):S11–S14PubMedPubMedCentralCrossRef

34.

Stolk MF, van Erpecum KJ, Koppeschaar HP, Samsom M, Smout AJ, Akkermans LM, Peeters TL, vanBerge-Henegouwen GP (1995) Effect of octreotide on fasting gall bladder emptying, antroduodenal motility, and motilin release in acromegaly. Gut. 36(5):755–760PubMedPubMedCentralCrossRef

35.

Poitras P, Trudel L, Miller P, Gu CM (1997) Regulation of motilin release: studies with ex vivo perfused canine jejunum. Am J Physiol. 272(1 Pt 1):G4–G9PubMed

36.

Ambartsumyan L, Flores A, Nurko S, Rodriguez L (2016) Utility of octreotide in advancing enteral feeds in children with chronic intestinal pseudo-obstruction. Paediatr Drugs. 18(5):387–392PubMedCrossRef

37.

Peeters TL, Romanski KW, Janssens J, Vantrappen G (1988) Effect of the long-acting somatostatin analogue SMS 201-995 on small-intestinal interdigestive motility in the dog. Scand J Gastroenterol. 23(7):769–774PubMedCrossRef

38.

Haruma K, Wiste JA, Camilleri M (1994) Effect of octreotide on gastrointestinal pressure profiles in health and in functional and organic gastrointestinal disorders. Gut. 35(8):1064–1069PubMedPubMedCentralCrossRef

39.

van Berge Henegouwen MI, van Gulik TM, Akkermans LM, Jansen JB, Gouma DJ (1997) The effect of octreotide on gastric emptying at a dosage used to prevent complications after pancreatic surgery: a randomised, placebo controlled study in volunteers. Gut. 41(6):758–762PubMedCrossRef

40.

Edmunds MC, Chen JD, Soykan I, Lin Z, McCallum RW (1998) Effect of octreotide on gastric and small bowel motility in patients with gastroparesis. Aliment Pharmacol Ther. 12(2):167–174PubMedCrossRef

41.

Richards WO, Geer R, O’Dorisio TM et al (1990) Octreotide acetate induces fasting small bowel motility in patients with dumping syndrome. J Surg Res. 49(6):483–487PubMedCrossRef

42.

Cullen JJ, Eagon JC, Kelly KA (1994) Gastrointestinal peptide hormones during postoperative ileus. Effect of octreotide. Dig Dis Sci. 39(6):1179–1184PubMedCrossRef

43.

Nordesjo-Haglund G, Lonnqvist B, Lindberg G, Hellstrom-Lindberg E (1999) Octreotide for nausea and vomiting after chemotherapy and stem-cell transplantation. Lancet. 353(9155):846PubMedCrossRef

44.

Soudah HC, Hasler WL, Owyang C (1991) Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma. N Engl J Med. 325(21):1461–1467PubMedCrossRef

45.

Lecomte T, Cavicchi M, Delchier JC (2000) Small bowel pseudo-obstruction revealing an early scleroderma. Long-term efficacy of octreotide and erythromycin. Gastroenterol Clin Biol. 24(3):361–363PubMed

46.

Dahaba AA, Mueller G, Mattiassich G, Rumpold-Seitlinger G, Bornemann H, Rehak PH, Linck G, Mischinger HJ, Metzler H (2009) Effect of somatostatin analogue octreotide on pain relief after major abdominal surgery. Eur J Pain. 13(8):861–864PubMedCrossRef

47.

Cullen JJ, Eagon JC, Dozois EJ, Kelly KA (1993) Treatment of acute postoperative ileus with octreotide. Am J Surg. 165(1):113–119 discussion 119-120PubMedCrossRef

48.

Wu Z, Wang S, Yuan S, Lin M (2020) Clinical efficacy and safety of somatostatin in the treatment of early postoperative inflammatory small bowel obstruction: a protocol for systematic review and meta analysis. Medicine (Baltimore). 99(20):e20288PubMedPubMedCentralCrossRef

49.

Guignard JP, Herxheimer A, Greenwood RM (1968) Effects of hyoscine butylbromide on gut motility. Clin Pharmacol Ther. 9(6):745–748PubMedCrossRef

50.

Herxheimer A, de Groot AC (1977) Some effects of injected hyoscine butylbromide: a versatile class experiment in human pharmacology. Br J Clin Pharmacol. 4(3):337–342PubMedPubMedCentralCrossRef

51.

Herxheimer A (1958) A comparison of some atropine-like drugs in man, with particular reference to their end-organ specificity. Br J Pharmacol Chemother. 13(2):184–192PubMedPubMedCentralCrossRef

52.

Deakin M, Williams JG (1992) Histamine H2-receptor antagonists in peptic ulcer disease. Efficacy in healing peptic ulcers. Drugs. 44(5):709–719PubMedCrossRef

53.

Konturek SJ, Radecki T, Brzozowski T, Piastucki I, Dembinska-Kiec A, Zmuda A (1981) Gastric cytoprotection by prostaglandins, ranitidine, and probanthine in rats. Role of endogenous prostaglandins. Scand J Gastroenterol. 16(1):7–12PubMed

54.

Katsoulis S, Conlon JM (1989) Calcitonin gene-related peptides relax guinea pig and rat gastric smooth muscle. Eur J Pharmacol. 162(1):129–134PubMedCrossRef

55.

Tache Y, Pappas T, Lauffenburger M, Goto Y, Walsh JH, Debas H (1984) Calcitonin gene-related peptide: potent peripheral inhibitor of gastric acid secretion in rats and dogs. Gastroenterology. 87(2):344–349PubMedCrossRef

56.

Bauerfeind P, Hof R, Hof A, Cucala M, Siegrist S, von Ritter C, Fischer JA, Blum AL (1989) Effects of hCGRP I and II on gastric blood flow and acid secretion in anesthetized rabbits. Am J Physiol. 256(1 Pt 1):G145–G149PubMed

57.

Itoh H, Naito T, Takeyama M (2002) Effects of histamine H(2)-receptor antagonists on human plasma levels of calcitonin gene-related peptide, substance P and vasoactive intestinal peptide. J Pharm Pharmacol. 54(11):1559–1563PubMedCrossRef

58.

Bertaccini G, Scarpignato C (1982) Histamine H2-antagonists modify gastric emptying in the rat. Br J Pharmacol. 77(3):443–448PubMedPubMedCentralCrossRef

59.

Ueki S, Seiki M, Yoneta T, Aita H, Chaki K, Hori Y, Morita H, Tagashira E, Itoh Z (1993) Gastroprokinetic activity of nizatidine, a new H2-receptor antagonist, and its possible mechanism of action in dogs and rats. J Pharmacol Exp Ther. 264(1):152–157PubMed

60.

Geppetti P, Del Bianco E, Patacchini R, Santicioli P, Maggi CA, Tramontana M (1991) Low pH-induced release of calcitonin gene-related peptide from capsaicin-sensitive sensory nerves: mechanism of action and biological response. Neuroscience. 41(1):295–301PubMedCrossRef

61.

Manela FD, Ren J, Gao J, McGuigan JE, Harty RF (1995) Calcitonin gene-related peptide modulates acid-mediated regulation of somatostatin and gastrin release from rat antrum. Gastroenterology. 109(3):701–706PubMedCrossRef

62.

Shimatani T, Inoue M, Kuroiwa T, Xu J, Nakamura M, Tazuma S, Ikawa K, Morikawa N (2006) Lafutidine, a newly developed antiulcer drug, elevates postprandial intragastric pH and increases plasma calcitonin gene-related peptide and somatostatin concentrations in humans: comparisons with famotidine. Dig Dis Sci. 51(1):114–120PubMedCrossRef

63.

Yang HX, Luo D, Zou YY (2007) Effect of ranitidine on the gastric acid, plasma endothelin, and calcitonin gene-related peptide in patients undergoing the brain operation. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 32(2):295–298PubMed

64.

Ren J, Young RL, Lassiter DC, Rings MC, Harty RF (1992) Calcitonin gene-related peptide: mechanisms of modulation of antral endocrine cells and cholinergic neurons. Am J Physiol. 262(4 Pt 1):G732–G739PubMed

65.

Ren J, Dunn ST, Tang Y, Wang Y, Gao J, Brewer K, Harty RF (1998) Effects of calcitonin gene-related peptide on somatostatin and gastrin gene expression in rat antrum. Regul Pept. 73(2):75–82PubMedCrossRef

66.

Sandvik AK, Dimaline R, Forster ER, Evans D, Dockray GJ (1993) Differential control of somatostatin messenger RNA in rat gastric corpus and antrum. Role of acid, food, and capsaicin-sensitive afferent neurons. J Clin Invest. 91(1):244–250PubMedPubMedCentralCrossRef

67.

Feuer DJ, Broadley KE (2000) Corticosteroids for the resolution of malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer. Cochrane Database Syst Rev. 2:CD001219

68.

Feuer DJ, Broadley KE (1999) Systematic review and meta-analysis of corticosteroids for the resolution of malignant bowel obstruction in advanced gynaecological and gastrointestinal cancers. Systematic Review Steering Committee. Ann Oncol. 10(9):1035–1041PubMedCrossRef

Title: Medical management of malignant bowel obstruction in patients with advanced cancer: 2021 MASCC guideline update
Authors: Mellar Davis
David Hui
Andrew Davies
Carla Ripamonti
Andreia Capela
Giulia DeFeo
Egidio Del Fabbro
Eduardo Bruera
Publication date: 01-12-2021
Publisher: Springer Berlin Heidelberg
Keywords: Nausea
Vomiting
Ranitidine
Haloperidol
Olanzapine
Published in: Supportive Care in Cancer / Issue 12/2021
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-021-06438-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Method

Results

Discussion

Conclusion

Please log in to get access to this content

Other articles of this Issue 12/2021

The application of “Omics” to accelerate precision medicine in Supportive Care in Cancer

The incidence and risk factors of low anterior resection syndrome (LARS) after sphincter-preserving surgery of rectal cancer: a systematic review and meta-analysis

Goals of care discussions: perceptions of radiation and medical oncologists

Moderators of intervention efficacy for Finding My Way: A web-based psychosocial intervention for cancer-related distress

The role of teledentistry in oral cancer patients during the COVID-19 pandemic: an integrative literature review

Neuropathy severity at the time of oxaliplatin treatment alteration in patients with colon cancer (Alliance A151912)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer